Screening for urologic malignancies in primary care: Pros, cons, and recommendations

Article Type
Changed
Tue, 09/25/2018 - 14:56
Display Headline
Screening for urologic malignancies in primary care: Pros, cons, and recommendations
Article PDF
Author and Disclosure Information

Andrew J. Stephenson, MD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Louis Kuritzky, MD
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL

Steven C. Campbell, MD, PhD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Correspondence: Steven C. Campbell, MD, PhD, Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195; campbes3@ccf.org

Drs. Stephenson and Campbell reported that they have no financial relationships that pose a potential conflict of interest with this article.

Dr. Kuritzky reported that he has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking.

Publications
Page Number
S6-S14
Author and Disclosure Information

Andrew J. Stephenson, MD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Louis Kuritzky, MD
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL

Steven C. Campbell, MD, PhD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Correspondence: Steven C. Campbell, MD, PhD, Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195; campbes3@ccf.org

Drs. Stephenson and Campbell reported that they have no financial relationships that pose a potential conflict of interest with this article.

Dr. Kuritzky reported that he has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking.

Author and Disclosure Information

Andrew J. Stephenson, MD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Louis Kuritzky, MD
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL

Steven C. Campbell, MD, PhD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Correspondence: Steven C. Campbell, MD, PhD, Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195; campbes3@ccf.org

Drs. Stephenson and Campbell reported that they have no financial relationships that pose a potential conflict of interest with this article.

Dr. Kuritzky reported that he has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking.

Article PDF
Article PDF
Page Number
S6-S14
Page Number
S6-S14
Publications
Publications
Article Type
Display Headline
Screening for urologic malignancies in primary care: Pros, cons, and recommendations
Display Headline
Screening for urologic malignancies in primary care: Pros, cons, and recommendations
Citation Override
Cleveland Clinic Journal of Medicine 2007 May;74(suppl 3):S6-S14
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media